GlassScriptPhysician profile
Marie Rivas
NPI 1730572512
$12,926.90
in general payments reported to CMS, 2019-2025
29 companies · $4,283 in 2025
The $4,283 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $855 · 2022: $719 · 2023: $4,276 · 2024: $2,795 · 2025: $4,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,508 · Travel and Lodging: $2,845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,507.86 |
| Travel and Lodging | $2,845.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $3,758.24 | 2022-2025 | Barostim Neo System |
| Abbott Laboratories | $1,976.97 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Impulse Dynamics (USA) INC. | $1,382.32 | 2024-2025 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $1,018.38 | 2021-2025 | Farxiga, Wainua |
| Novartis Pharmaceuticals Corporation | $777.78 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $457.38 | 2023-2025 | Camzyos |
| Abiomed | $422.16 | 2024-2025 | Impella |
| Pfizer INC. | $412.39 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $370.19 | 2021-2024 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $349.10 | 2023-2024 | Inpefa |
| Alnylam Pharmaceuticals INC. | $339.42 | 2021-2025 | Amvuttra, Onpattro |
| Scpharmaceuticals INC. | $336.50 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $302.27 | 2021-2025 | Verquvo, Capvaxive |
| Ancora Heart, INC. | $163.82 | 2025 | Accucinch |
| Boston Scientific Corporation | $155.86 | 2022-2024 | Watchman Flx, Watchman Access System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $146.59 | 2021-2025 | Jardiance |
| Daiichi Sankyo INC. | $105.57 | 2022-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $82.96 | 2024-2025 | |
| Actelion Pharmaceuticals US, INC. | $53.45 | 2023-2024 | Opsumit, Uptravi |
| Analog Devices INC. | $50.00 | 2025 | Sensinel Cpm Wearable |
| Amgen INC. | $45.90 | 2023-2025 | Repatha, Repatha |
| Novo Nordisk INC | $37.26 | 2023-2024 | Rybelsus, Ozempic |
| Heartflow, INC. | $36.24 | 2023-2025 | Ffrct |
| Janssen Pharmaceuticals, INC | $31.53 | 2021-2024 | Xarelto |
| Bridgebio Pharma, INC. | $30.23 | 2025 | Attruby |
| Edwards Lifesciences Corporation | $26.82 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Esperion Therapeutics, INC. | $21.01 | 2024 | Nexletol |
| Vifor Pharma, INC. | $20.78 | 2021 | |
| Chiesi USA, INC. | $15.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marie Rivas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.